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Abstract
The International Breast Cancer Study Group (IBCSG) has been
conducting large, phase III clinical trials since 1978. Prior to 1986,
these activities were carried out under the name of Ludwig Breast
Cancer Study Group. Seven trials of adjuvant therapies are
currently open for patient accrual, five of which are described in
this report. The IBCSG has been a leader in the field of tailored
treatment approaches for specific subpopulations of patients with
breast cancer, believing that what is best for the majority may not
be best for a defined minority.
Introduction
The International Breast Cancer Study Group (IBCSG)
opened its first generation of trials in 1978. The IBCSG
includes both participating cooperative groups and individual
institutions from all over the world. The groups are from
Switzerland (Swiss Group for Clinical Cancer Research, 38
centers), Sweden (West Sweden Breast Cancer Study
Group, 11 centers), Australia and New Zealand (Australian
New Zealand Breast Cancer Trials Group, 56 centers), and
Chile (GOCCHI, a Chilean cooperative group, 23 centers).
Individual centers are located in Italy (14 centers), Slovenia,
Hungary (2 centers), Spain, Romania, Austria, United
Kingdom, Belgium (2 centers), Brazil, Peru, Hong Kong, India,
South Africa (2 centers), and Canada.
The IBCSG is conducting trials of tailored treatment
approaches for these subpopulations: patients with
endocrine non-responsive early breast cancer; older patients
with endocrine non-responsive early breast cancer who are
not candidates for standard chemotherapy regimens; and
younger patients with endocrine responsive early breast
cancer. Because each of these three populations is
somewhat rare, treatment decisions tend to be based on the
findings from the largest breast cancer population: middle-
aged (median age 55) women with endocrine responsive
breast cancer (i.e. estrogen receptor-positive and/or
progesterone receptor-positive) who were included in trials of
chemotherapy and of endocrine therapy across the board.
Through subgroup analyses of these large heterogeneous
trials we have identified distinct responsiveness features, and
the current generation of IBCSG trials investigates
treatments tailored to populations based on these features
(Table 1). Examples of such trials are described below.
Tailored chemotherapy trial for women with
endocrine non-responsive breast cancer: the
CM-Maintenance trial
The CM-Maintenance Trial (IBCSG 22-00) studies a tailored
chemotherapy approach for patients with endocrine non-
responsive tumors. The role of prolonged, low-dose
chemotherapy after a standard adjuvant chemotherapy regimen
to reduce the risk of relapse and improve survival is being
investigated. Unlike patients with endocrine responsive disease,
who benefit from five years of endocrine therapy after
chemotherapy, there is no opportunity for a useful prolonged
treatment for patients with endocrine non-responsive disease
beyond a standard duration (six months). The low-dose
chemotherapy (metronomic) regimen used in this trial
(cyclophosphamide and methotrexate (CM) given orally) was
developed in advanced disease and resulted in tumor shrinkage
even in patients heavily pretreated [1]. This combination of
drugs might be effective by damaging the tumors’ vessels (anti-
angiogenesis) or by interfering with progression of the stromal
structure of metastases. In the trial, one year of CM is compared
with no further therapy beyond the standard adjuvant program.
This ongoing trial was designed to allow a new drug with proven
anti-angiogenic effects, if one becomes available, to replace the
current metronomic regimen (CM).
As of June 30, 2005, 339 of the required 900 patients have
been enrolled from 22 participating centers. Accrual to the
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trial has been slower than anticipated, and the IBCSG is
actively seeking new participants.
Tailored chemotherapy trial for women at
advanced age with endocrine non-responsive
breast cancer: the CASA trial
Aging remains one of the single greatest risk factors for the
development of new breast cancer, with the estimated risk of
new breast cancer at 1 in 14 for women aged 60 to 79 years
compared with 1 in 24 women aged 40 to 59 years and 1 in
228 women aged 39 years and younger [2]. In western
countries, approximately 50% of women with breast cancer
are 65 years of age or older [3]. Because breast cancer
incidence increases with age, more cases can be expected
among elderly women [3]. Despite this fact, the appropriate
use of adjuvant chemotherapy for elderly women with breast
carcinoma remains unknown, especially for women with an
endocrine non-responsive early breast cancer who have no
opportunity to be treated for reduction of risk of relapse with
hormonal therapies. Even without considering endocrine
responsiveness, efficacy data in women aged >70 years are
scarce, resulting in a lack of clear guidelines for patients in
this age group. In the 2005 Overview Analysis [4], which
combined data from most of the clinical trials for patients with
early breast cancer, only 4% of the women enrolled in trials
with a comparison of multi-agent chemotherapy to nil were
aged 70 or older.
To accommodate physician and patient preferences, the
IBCSG has designed two complementary randomization
options within one clinical trial, Trial 32-05 (CASA), to
investigate the role of adjuvant cytotoxic chemotherapy for
women at advanced age with endocrine non-responsive early
breast cancer who are not suitable for one of the standard
chemotherapy regimens. Pegylated liposomal doxorubicin
(PLD) is the experimental treatment. For each eligible patient,
the investigator will choose one of the two randomization
options based on physician and/or patient preference. Option
1, CASA-nil: PLD versus nil, for patients who are candidates
to receive no adjuvant therapy. Option 2, CASA-CM: PLD
versus CM, for patients who should receive some adjuvant
treatment.
The primary evaluation will be to compare PLD versus non-
PLD-containing regimens in the pooled analysis of both
pairwise comparisons.
The CASA trial was distributed in August 2005 for
participating center approval and activation. The total
required sample size is 1,296 patients.
Tailored treatment investigations for
premenopausal women with endocrine
responsive breast cancer: the SOFT, TEXT,
and PERCHE (STP) trials
The STP trials are complementary studies designed to
answer three open questions concerning adjuvant treatment
for premenopausal patients with endocrine responsive
disease: What is the role of ovarian function ablation/
suppression (OFS)? What is the role of aromatase inhibitors?
What is the role of chemotherapy? We know that chemo-
therapy, tamoxifen and OFS are individually effective adjuvant
treatment modalities in women under 50 years of age with
estrogen receptor-positive breast cancer [5,6]. The addition
Table 1
International Breast Cancer Study Group tailored treatment trials (trials presented in this report)
IBCSG Trial Population Activation Target accrual Comparison(s)
CM-maintenance Endocrine non-responsive November 2000 900 Induction CT versus
IBCSG 22-00 Induction CT → CM 
maintenance
CASA Endocrine non-responsive,  August 2005 1,296 Option 1: PLD versus nil
IBCSG 32-05 older, not suitable for  Option 2: PLD versus low 
standard CT dose CM
SOFT Premenopausal at  August 2003 3,000 Tamoxifen alone versus 
IBCSG 24-02 randomization OFS + tamoxifen versus 
OFS + exemestane
TEXT Should get OFS at start August 2003 1,845 Triptorelin ± CT + tamoxifen 
IBCSG 25-02 versus triptorelin ± CT + 
exemestane
PERCHE Should get OFS at start,  August 2003 1,750 OFS + (tamoxifen or 
IBCSG 26-02 lower risk exemestane) versus OFS + 
CT + (tamoxifen or 
exemestane)
CM, cyclophosphamide and methotrexate; CT = chemotherapy; IBCSG = International Breast Cancer Study Group; OFS = ovarian function
suppression; PLD = pegylated liposomal doxorubicin.254
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of 5 years of tamoxifen to adjuvant chemotherapy in this
group results in an additional approximately 40% reduction in
the odds of recurrence or death [7,8]. These data suggest
that adjuvant combination chemo-endocrine strategies can
improve results over single modality treatments.
Conclusive data on the best approaches to treat this
population are scarce because positive results for
chemotherapy in the 1970s (mainly for women in their forties)
and misleading overview reports on tamoxifen (claimed to be
ineffective in younger women) in the 1980s and 1990s,
inhibited evaluation of endocrine therapies for younger
women. Adjuvant treatment of choice for individual pre-
menopausal women with endocrine responsive disease is
largely based upon assessment of risk of relapse and
physician’s perception on the relative role of endocrine
versus cytotoxic approaches. To offer a randomized clinical
trial to define a better adjuvant treatment for premenopausal
women with endocrine responsive disease, three tailored
treatment investigations are being conducted globally by the
IBCSG through the Breast International Group and the North
American Breast Intergroup.
The Suppression of Ovarian Function Trial (SOFT: IBCSG
24-02) is designed to determine the role of OFS and the role
of aromatase inhibitors for women who remain premeno-
pausal after surgery alone or after completion of adjuvant
and/or neoadjuvant chemotherapy.
The Tamoxifen and Exemestane Trial (TEXT: IBCSG 25-02)
is designed to determine the role of aromatase inhibitors for
women who receive OFS (with triptorelin) from the start of
adjuvant therapy. Chemotherapy, if given, should be started
with the triptorelin and followed by the tamoxifen or
exemestane. Use of chemotherapy is by investigator/patient
choice or by randomized assignment in the PERCHE trial.
The Premenopausal Endocrine Responsive Chemotherapy
Trial (PERCHE: IBCSG 26-02) is designed to determine the
role of chemotherapy. It features randomization either to OFS
plus tamoxifen or exemestane, or to chemotherapy plus OFS
plus tamoxifen or exemestane. Women for whom the role of
adding chemotherapy to ‘complete estrogen blockade’ is
uncertain should be offered PERCHE.
As of June 30, 2005, 164 participating centers from North
America, Europe, Australia, South America, and Africa have
randomized patients on these trials, including 243 on SOFT,
432 on TEXT, and 10 on PERCHE. The total required sample
size is 3,000, 1,845 and 1,750 patients, respectively.
Translational research in CASA,
CM-maintenance, and STP
All of the trials include collection of tissue blocks (both tumor
and normal) for translational research. Central laboratory
assessments of estrogen and progesterone receptor
(immunohistochemical percent stained cells), HER-2/neu, Ki-
67, grade, and histological type are planned. Translational
research projects proposed by scientists among IBCSG
members or outside the Group are encouraged. Definition of
new subgroups of patients within the endocrine non-
responsive population of the CASA trial, differential
responsiveness patterns to tamoxifen or to exemestane by
hormone receptors and HER-2/neu for patients in the STP
trials, and the evaluation of several angiogenesis and stromal
markers in the CM-Maintenance trial are ongoing or planned.
This translational research will provide the scientific
foundation for the therapeutic trials conducted in specific
populations.
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